Chugai Pharmaceutical (CHGCF) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you very much for attending the conference on FY 2020 for December financial results for Chugai Pharmaceutical. I am acting as a master of ceremony for today. My name is Miyata from IR department. We are holding this session in a hybrid manner. The agenda for today's presentation are shown on the presentation material page 3 on the screen in the venue. However, for those who are participating through Zoom webinar, you will be able to hear simultaneous translation. Please select the language of your choice by clicking the button at the bottom of your screen. For those who wish to listen to Japanese, please select Japanese. English, please select English. After selecting your preferred language, please click on mute original audio. At the beginning of each session, we are going to pose for a while for those to take a photo of the screen. We are going to take questions at the very end of the presentation. We allocate about 30 minutes for Q&A session. Your audio is muted during the presentation session. Now, Okuda will take you to the summary of year 2024 and outlook into 2025. We are going to pause for a while before the presentation of Okuda, so for those who wish to take screen capture, please do so. Now, I'd like to start the presentation. I am Okuda, the President. I'll explain the summary of 2024 and the forecast for 2025. Please take a look at page 4 of the slides. The four-year results of 2024 exceeded the revised forecast for revenue, operating profit, and net income, with all figures reaching record highs. Revenue exceeded ¥1 trillion for the third consecutive year, and operating profit exceeded ¥500 billion for the first time. The operating margin also reached a record high of 47.5%. Regarding domestic sales, the completion of 81.2 ...